Preventing cardiovascular events with empagliflozin: at what cost?

Naci, Huseyin ORCID: 0000-0002-7192-5751, Basu, Sanjay and Yudkin, John S (2015) Preventing cardiovascular events with empagliflozin: at what cost? The Lancet Diabetes and Endocrinology, 3 (12). p. 931. ISSN 2213-8587

Preview

PDF - Accepted Version Download (185kB) | Preview

• Author

Abstract

The EMPA-REG OUTCOME study,1 as the first randomised trial to show that a glucose-lowering intervention was associated with reduced cardiovascular events,2 raises important questions for policy makers. Chief among these questions is whether the detected effect size produces a cost-effective risk reduction from the studied pharmacological approach. The study has undoubtedly brought good news for the trial funders: analysts predict that its findings will propel empagliflozin ahead of other glucose-lowering drugs in sales.

Item Type:	Article
Official URL:	http://www.thelancet.com/
Additional Information:	© 2015 Elsevier Ltd
Divisions:	LSE Health
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	26 Feb 2016 17:01
Last Modified:	12 Dec 2024 00:59
URI:	http://eprints.lse.ac.uk/id/eprint/65545

Actions (login required)

View Item